MLchartDataset catalogue

oncolytic VSV-GP BI 1821736

Term · Oncology and biomedicine · MLC-T-ONC-015668

An oncolytic virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP) and a human CD80 (B7.1) Fc fragment, with potential immunomodulating and antineoplastic activities. Upon administration, oncolytic VSV-GP BI 1821736 preferentially replicates in tumor cells, and induces VSV-mediated cytolytic activity towards the tumor cells. Viral infection also stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In addition, BI 1821736 secretes CD80, which targets and binds to CD28, and in the presence of antigenic T-cell receptor (TCR) signaling leads to the co-stimulation of T-cell responses including the activation of naive and memory T cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells.

Table 1. Record
IdentifierMLC-T-ONC-015668
FieldOncology and biomedicine
Synonymsoncolytic VSV-GP-huCD80Fc BI 1821736; VSV-GP BI 1821736
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015668",
  "term": "oncolytic VSV-GP BI 1821736",
  "field": "Oncology and biomedicine",
  "definition": "An oncolytic virus derived from the vesicular stomatitis virus (VSV), a single-stranded RNA virus, and containing a genetically modified glycoprotein (GP) and a human CD80 (B7.1) Fc fragment, with potential immunomodulating and antineoplastic activities. Upon administration, oncolytic VSV-GP BI 1821736 preferentially replicates in tumor cells, and induces VSV-mediated cytolytic activity towards the tumor cells. Viral infection also stimulates the immune system to recognize these same tumor cells, leading to immune-mediated killing of both infected and non-infected tumor cells, thereby further killing tumor cells. In addition, BI 1821736 secretes CD80, which targets and binds to CD28, and in the presence of antigenic T-cell receptor (TCR) signaling leads to the co-stimulation of T-cell responses including the activation of naive and memory T cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells.",
  "synonyms": [
    "oncolytic VSV-GP-huCD80Fc BI 1821736",
    "VSV-GP BI 1821736"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/oncolytic-vsv-gp-bi-1821736/"
}

Record 12,234 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.